Clinical trial TiNivo-2
A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination with Nivolumab to Tivozanib Monotherapy in Subjects with Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line has an Immune Checkpoint Inhibitor
| Cancers | |
|---|---|
| Organ | Kidney |
| Trial status | Trial closed for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | AVEO PHARMACEUTICALS, INC. |
| EudraCT Identifier | 2021-000050-26 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT04987203 |
| Last update |